What are common CRISPR delivery methods, and what are the trade-offs of plasmid-based vs ribonucleoprotein (RNP) delivery?

What are common CRISPR delivery methods, and what are the trade-offs of plasmid-based vs ribonucleoprotein (RNP) delivery?

• A. Plasmid DNA, viral vectors, or ribonucleoprotein (RNP) delivery; plasmids provide sustained expression but higher off-target risk; RNP yields transient activity with potentially fewer off-targets.
• B. Only plasmid DNA can be used.
• C. RNP delivery yields permanent edits with higher off-target risk.
• D. CRISPR cannot be delivered as viral vectors.

Answer: (B)

The key idea here is how long the genome editors stay active inside cells and how that affects editing outcomes. Common CRISPR delivery methods include plasmid DNA, viral vectors, and pre-assembled ribonucleoprotein complexes (RNPs). Plasmid DNA delivery works by introducing DNA that encodes the Cas protein and the guide RNA. The cell then transcribes and translates these components, leading to ongoing expression for as long as the plasmid remains active. This sustained activity can boost editing efficiency in some systems, but it also raises the risk of more off-target edits because Cas9 is present for an extended period. There’s also a chance of unintended DNA persistence or integration events in certain contexts. RNP delivery puts the active CRISPR machinery directly into the cell as a complex of Cas9 protein and guide RNA. This approach provides a brief burst of activity that is typically enough to achieve the desired edit and then rapidly diminishes as the components are degraded. The transient presence often reduces off-target editing and avoids introducing DNA into the genome, which is a safety advantage. However, delivering RNPs can be more technically challenging and may require optimization to achieve efficient delivery in different cell types or tissues, and dosing can be more demanding to hit the same overall editing level as plasmids in some cases. Viral vectors offer high delivery efficiency and can be tailored to target specific cell types, but they bring their own trade-offs, including potential immune responses and, depending on the vector, concerns about genomic integration and safety. So, when comparing plasmid-based delivery to RNP delivery, the main trade-offs are duration of Cas9 activity and consequent off-target risk versus delivery ease and the safety profile, with RNPs generally offering more transient activity and potentially fewer off-target effects, and plasmids offering easier, sometimes more robust expression but at the cost of longer exposure.

The key idea here is how long the genome editors stay active inside cells and how that affects editing outcomes. Common CRISPR delivery methods include plasmid DNA, viral vectors, and pre-assembled ribonucleoprotein complexes (RNPs).

Plasmid DNA delivery works by introducing DNA that encodes the Cas protein and the guide RNA. The cell then transcribes and translates these components, leading to ongoing expression for as long as the plasmid remains active. This sustained activity can boost editing efficiency in some systems, but it also raises the risk of more off-target edits because Cas9 is present for an extended period. There’s also a chance of unintended DNA persistence or integration events in certain contexts.

RNP delivery puts the active CRISPR machinery directly into the cell as a complex of Cas9 protein and guide RNA. This approach provides a brief burst of activity that is typically enough to achieve the desired edit and then rapidly diminishes as the components are degraded. The transient presence often reduces off-target editing and avoids introducing DNA into the genome, which is a safety advantage. However, delivering RNPs can be more technically challenging and may require optimization to achieve efficient delivery in different cell types or tissues, and dosing can be more demanding to hit the same overall editing level as plasmids in some cases.

Viral vectors offer high delivery efficiency and can be tailored to target specific cell types, but they bring their own trade-offs, including potential immune responses and, depending on the vector, concerns about genomic integration and safety.

So, when comparing plasmid-based delivery to RNP delivery, the main trade-offs are duration of Cas9 activity and consequent off-target risk versus delivery ease and the safety profile, with RNPs generally offering more transient activity and potentially fewer off-target effects, and plasmids offering easier, sometimes more robust expression but at the cost of longer exposure.